Current Price and Market Context
As of 2 Jan 2026, Mankind Pharma’s share price closed at ₹2,163.10, down 1.51% from the previous close of ₹2,196.35. The stock traded within a range of ₹2,160.00 to ₹2,213.50 during the day, remaining closer to its 52-week low of ₹2,090.10 than its high of ₹2,998.45. This price action reflects ongoing pressure amid broader market volatility.
Technical Trend Overview
The technical trend for Mankind Pharma has shifted from outright bearish to mildly bearish on a weekly basis, indicating a slight easing of downward momentum but no clear reversal yet. The daily moving averages remain bearish, suggesting that short-term price action continues to face resistance. Meanwhile, monthly trends show no definitive signals, underscoring uncertainty in longer-term direction.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly chart, signalling that the stock’s momentum is still tilted towards the downside. The absence of a monthly MACD signal further emphasises the lack of strong directional conviction over a longer horizon. This bearish MACD reading aligns with the recent price decline and the stock’s failure to sustain levels above key moving averages.
RSI and Relative Strength
Contrasting the MACD, the Relative Strength Index (RSI) on the weekly timeframe has turned bullish, suggesting that the stock may be approaching oversold conditions and could be poised for a short-term rebound. However, the monthly RSI remains neutral with no clear signal, indicating that any recovery may be limited or temporary without broader market support.
Bollinger Bands and Volatility
Bollinger Bands on both weekly and monthly charts remain bearish, reflecting sustained volatility and downward price pressure. The stock’s current price is near the lower band, which often acts as a support level but also signals heightened risk of further declines if breached decisively.
Other Technical Measures
The Know Sure Thing (KST) indicator is mildly bearish on the weekly chart, reinforcing the cautious outlook. Meanwhile, the Dow Theory on a weekly basis shows a mildly bullish stance, hinting at some underlying strength in the broader trend, though this is not yet confirmed on monthly charts. On-Balance Volume (OBV) is mildly bullish weekly, suggesting that volume flow may be supporting price stability despite the recent dip.
Comparative Performance Against Sensex
Over the past week, Mankind Pharma’s stock return was -1.42%, significantly underperforming the Sensex’s modest decline of -0.26%. The one-month return shows a sharper drop of -3.0% compared to the Sensex’s -0.53%. Year-to-date, the stock has declined by 1.51%, while the Sensex has remained almost flat with a -0.04% return. Over the last year, the stock has suffered a steep 25.3% loss, in stark contrast to the Sensex’s 8.51% gain. These figures highlight the stock’s relative weakness within the broader market and sector.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Mojo Score and Grade Revision
Mankind Pharma’s Mojo Score currently stands at 44.0, reflecting a weak technical and fundamental outlook. The Mojo Grade was downgraded from Hold to Sell on 19 Nov 2025, signalling a deterioration in the stock’s quality and momentum. The Market Cap Grade remains at 1, indicating a relatively small market capitalisation compared to peers, which may contribute to higher volatility and risk.
Moving Averages and Daily Price Action
Daily moving averages continue to exert bearish pressure, with the stock trading below key averages such as the 50-day and 200-day moving averages. This technical positioning suggests that short-term sellers remain in control, and any rallies may face resistance near these levels. The daily price range between ₹2,160.00 and ₹2,213.50 indicates limited intraday volatility but a clear downward bias.
Volume and On-Balance Volume Analysis
The On-Balance Volume (OBV) indicator on a weekly basis is mildly bullish, implying that despite price declines, there is some accumulation by investors. This divergence between price and volume could signal a potential base formation or a pause in selling pressure. However, the lack of a monthly OBV trend tempers enthusiasm for a sustained recovery.
Sector and Industry Context
Operating within the Pharmaceuticals & Biotechnology sector, Mankind Pharma faces sector-wide challenges including regulatory scrutiny, pricing pressures, and competitive dynamics. The stock’s underperformance relative to the Sensex and sector peers suggests that investors are cautious about its near-term growth prospects and risk profile.
Holding Mankind Pharma Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway and Outlook
In summary, Mankind Pharma Ltd’s technical indicators present a mixed but predominantly cautious picture. The weekly MACD and Bollinger Bands remain bearish, while the RSI and OBV offer some mild bullish hints. The downgrade to a Sell grade and the stock’s underperformance relative to the Sensex underscore the risks involved. Investors should closely monitor the stock’s ability to hold above key support levels near ₹2,090 and watch for any sustained improvement in moving averages and momentum indicators before considering fresh exposure.
Given the current technical and fundamental backdrop, a conservative approach is advisable. Those holding the stock may consider evaluating alternative investments within the Pharmaceuticals & Biotechnology sector that demonstrate stronger momentum and higher Mojo Scores.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
